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Depression is one of the major global health challenges and a leading contributor of
health related disability and costs. Depression is a heterogeneous disorder and current
methods for assessing its severity in clinical practice rely on symptom count, however this
approach is unreliable and inconsistent. The clinical evaluation of depressive symptoms is
particularly challenging in primary care, where the majority of patients with depression are
managed, due to the presence of co-morbidities. Current methods for risk assessment
of depression do not accurately predict treatment response or clinical outcomes. Several
biological pathways have been implicated in the pathophysiology of depression; however,
accurate and predictive biomarkers remain elusive. We conducted a systematic review of
the published evidence supporting the use of peripheral biomarkers to predict outcomes in
depression, using Medline and Embase. Peripheral biomarkers in depression were found
to be statistically significant predictors of mental health outcomes such as treatment
response, poor outcome and symptom remission; and physical health outcomes such as
increased incidence of cardiovascular events and deaths, and all-cause mortality. However,
the available evidence has multiple methodological limitations which must be overcome
to make any real clinical progress. Despite extensive research on the relationship of
depression with peripheral biomarkers, its translational application in practice remains
uncertain. In future, peripheral biomarkers identified with novel techniques and combining
multiple biomarkers may have a potential role in depression risk assessment but further
research is needed in this area.
Keywords: peripheral biomarkers, depression, treatment response, risk assessment, outcomes
INTRODUCTION
HETEROGENEITY IN DEPRESSIVE SYMPTOMS
Depression is a heterogeneous disorder with a spectrum ranging
from minor/sub threshold to major depressive disorder (MDD)
(Rodriguez et al., 2012). According to the latest global disease bur-
den study, depressive disorders (MDD and sub threshold/minor
depression) are the leading cause of disability and disease burden
globally (Ferrari et al., 2013). The methods currently available
for risk assessment and stratification of symptom severity for
patients presenting with depressive symptoms rely predominantly
on counting the absolute number of depressive symptoms present
but there is no universally accepted standardized definition. The
Diagnostics and Statistical Manual (DSM)-IV’s diagnosis of a
MDD requires the presence of at least 5 out of 9 symptoms of
depression with significant impairment or distress, while those
presenting with at least 2 but less than 5 symptoms and no
previous history of MDD are stratified as sub threshold or
minor depression (American Psychiatric Association, 2000). The
category of sub threshold depression has been removed from
recently published DSM-V (American Psychiatric Association,
2013). On the other hand, the International Classification of
Diseases (ICD-10) stratifies depressive symptoms on the basis
of the number of depressive symptoms present into mild (4 out
of 10), moderate (5 or 6 out of 10) and severe (7 or more out
of 10) depressive episode (WHO, 2010). However, this approach
has been questioned owing to lack of consensus (Wittchen et al.,
2001; Hegerl et al., 2012) and because it ignores the complexity
and diversity of depressive symptoms (Goldberg, 2011). The bulk
of patients reporting with depressive symptoms are managed in
primary care; however the rate of accurate stratification of depres-
sive symptoms in primary care was less than 50% based on a
meta-analysis involvingmore than 50,000 patients (Mitchell et al.,
2009). Minor or sub threshold depression has been associated
with severe deficits in psychological well-being and quality of life,
progression to major disorder and increased mortality (Cuijpers
and Smit, 2002; Lyness et al., 2006; Nierenberg et al., 2010),
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underlining the need for its early identification and appropriate
treatment.
MANAGEMENT OF DEPRESSION
The uncertainty in stratifying depression severity based on symp-
tom count affects subsequent management. A review of treat-
ment guidelines for depression across North America and Europe
revealed that “mild MDD and sub threshold depression has the
most variance in recommendations”; with suggested approaches
ranging from watchful waiting to active treatment with antide-
pressants (Davidson, 2010). In the last decade, three separate
meta-analyses reported that the efficacy of antidepressants is
related to the initial severity of depression and they may not be
effective in the treatment of mild depression (Khan et al., 2002;
Kirsch et al., 2008; Fournier et al., 2010). However, this view has
been challenged recently with emerging evidence suggesting that
the efficacy of antidepressants in depression may not be related
to its initial severity (Gibbons et al., 2012; Fountoulakis et al.,
2013). Psychological therapies have been found to be effective in
the management of mild depression but they have not been sub-
jected to the same level of scrutiny as pharmacological therapies as
yet (Cuijpers et al., 2007). The ambiguity surrounding stratifying
the severity of depression based on symptom count and its sub-
sequent management could partially explain why most patients
with depression do not receive adequate treatment and many
treated patients develop treatment resistance and relapse (Thase,
2006; Nemeroff, 2007). Therefore, different approaches for risk
assessment and severity stratification of patients presenting with
depressive symptoms are urgently required.
PATHOGENESIS OF DEPRESSION
The etiopathogenesis of depression has been extensively studied
over the last five decades with various explanatory mechanisms
involving different physiological systems, suggesting heterogene-
ity (Zunszain et al., 2011). The “monoamine hypothesis of
depression” was proposed in the 1960s with early work show-
ing increased levels of plasma tryptophan (serotonin precursor)
in patients with major depression (Coppen et al., 1973). Failure
to suppress cortisol in response to dexamethasone in patients
with depression was the initial finding which supported the role
of hypothalamic-pituitary-adrenal (HPA) axis hyperactivity in
the pathophysiology of depression (Carroll et al., 1981). The
“cytokine hypothesis” suggests that depression is triggered, in
part, via inflammatory processes in response to various internal
and external stressors, following some seminal work in the early
1990s (Maes et al., 1991). This hypothesis has been further devel-
oped to suggest that inflammatory, oxidative and nitrosative stress
are causally related to depression and increased translocation of
lipopolysaccharide from gram negative bacteria may aggravate
these pathways (Maes, 2008). The “neurogenesis hypothesis” of
depression proposes that depression is characterized by neurode-
generation and impaired neurogenesis in the brain, in particular
the hippocampus region (Sapolsky, 2004). The bi-directional
relationship between metabolic syndrome and depression and
their common pathophysiological pathways has been reported
extensively (McIntyre et al., 2009; Vancampfort et al., 2013). Of
course, several hypotheses may overlap or be relevant here.
BIOMARKERS OF DEPRESSION
A biomarker can be defined as a characteristic that is objec-
tively measured and evaluated as an indicator of normal biologic
processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention (Biomarkers Definitions Working
Group, 2001). The research into pathogenesis of depression has
led to a strong evidence base supporting a cross-sectional rela-
tionship between depressive symptoms and a number of differ-
ent biomarkers pertaining to some of the physiological systems
described above, but their role, if any, in predicting clinical out-
comes in depression remains unclear (Macaluso et al., 2012).
Peripheral biomarkers (blood based) are relatively non-invasive
(other than the need for a blood sample) and easier to measure;
hence they have a greater potential for translational application
into routine clinical practice, when compared to imaging, genetic
and CNS biomarkers. Peripheral biomarkers such as those related
to HPA axis, inflammatory and monoamine systems may have
a role in the diagnosis of depression by identifying a “biologi-
cal sub-type” of depression, and in prognostication of depression
by predicting treatment response, which in turn could help in its
severity stratification and management (Fisar and Raboch, 2008;
Leuchter et al., 2010; Schmidt et al., 2011). Various inflamma-
tory and oxidative stress biomarkers have been proposed to have
a potential role, not only in predicting antidepressant response,
but also in enhancing treatment matching and onset prediction in
patients with depression (Lopresti et al., 2014). For example, in a
study based on a multi-center trial involving depression patients,
showed an interaction between antidepressants and C-reactive
protein with patients with raised CRP more likely to respond to
nortripytline than escitalopram (Uher et al., 2014).
AIMS OF THE REVIEW
To attempt to address this issue, we examine the evidence base
exploring the potential role of peripheral biomarkers at base-
line in predicting future outcomes in patients with depression.
We discuss the potential role of peripheral biomarkers identi-
fied using novel and emerging techniques such as proteomics,
metabolomics, genetics, and epigenetics in risk assessment and
outcome prediction in patients with depressive symptoms. We
also review the relationship between depressive symptoms and
a composite index score derived using multiple peripheral
biomarkers such as allostatic index (AI) and discuss its possible
role in future, in management of depression.
METHODS
Two electronic databases (Ovid Medline and Embase) were
searched for studies published between 1946 and Jan 2013 using
the MESH terms “Biological markers” AND “Depression.” All
original and review studies using peripheral biomarkers at base-
line as a risk assessment tool for predicting future outcomes
in patients with depression were included. Clinical outcomes
pertaining to both mental health (e.g., depressive symptoms)
and physical health (e.g., cardiovascular event) were included.
Only studies published in English language were considered
for inclusion. Studies related to animal, imaging biomarkers,
cerebrospinal fluid biomarkers, and mood disorders other than
depression were excluded. Studies which investigated the role of
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depressive symptoms and peripheral biomarkers independently
in predicting adverse physical outcomes but did not examine
the interaction between depressive symptoms and peripheral
biomarkers, or in other words did not perform a sub-group
analysis in patients with depression, were excluded. Studies that
investigated changes in peripheral biomarker levels following
treatment for depression and which didn’t report any correla-
tion between baseline biomarker levels and depressive symptoms
were excluded as the aim of this review was to focus on the use of
peripheral biomarkers at baseline or pre-treatment as a predictive
tool of clinical outcome (both mental and physical), rather than
a change in biomarker level itself. The search strategy returned
1096 studies from two databases after excluding duplicates (see
Figure 1 for details).
Title, abstract and full text screening followed by reference and
citation searching and data extraction were carried out indepen-
dently by two researchers (Bhautesh D. Jani and Gary McLean).
The data extraction comprised of study sample size and country,
type of study and setting, details of how depression was diagnosed
and treated, follow-up duration, biomarkers assessed, clinical
outcomes studied and potential bias in the results. The descrip-
tion of methodology used by included studies for biomarker
measurement and the source of peripheral biomarker (i.e., serum
or plasma or whole blood) was also reviewed in data extraction.
RESULTS
INCLUDED STUDIES AND THEIR CHARACTERISTICS
There was extensive evidence (109 studies) exploring and sup-
porting the cross-sectional relationship between depression and
different peripheral biomarkers. However, only a minority of
studies (n = 14) explored the use of peripheral biomarkers to pre-
dict outcomes in patients with depression. Fifteen papers were
included for data extraction; which consisted of nine prospec-
tive cohort studies (Duval et al., 1996; Perez et al., 1998; Alvarez
et al., 1999; Johnston et al., 1999; Lanquillon et al., 2000; Ladwig
et al., 2005; Binder et al., 2009; Jokinen and Nordstrom, 2009;
Baune et al., 2012), three case-control studies (Arolt et al., 2003;
Baldwin et al., 2006; Jang et al., 2008), two randomized controlled
trials (Kin et al., 1997; Raison et al., 2013) and one meta-analysis
(Ribeiro et al., 1993). Full details of included studies are summa-
rized in Table 1.
Sample sizes ranged from 8 to 986 with sample sizes of less
than 50 participants in00206 studies (Duval et al., 1996; Alvarez
et al., 1999; Johnston et al., 1999; Lanquillon et al., 2000; Arolt
et al., 2003; Baldwin et al., 2006), while three studies had a sample
size of 25 or less (Alvarez et al., 1999; Lanquillon et al., 2000; Arolt
et al., 2003). Follow-up duration ranged from 4 weeks to 18 years
with the follow-up duration being less than 6 months in 9 stud-
ies(Duval et al., 1996; Kin et al., 1997; Perez et al., 1998; Alvarez
et al., 1999; Lanquillon et al., 2000; Arolt et al., 2003; Jang et al.,
2008; Binder et al., 2009; Raison et al., 2013) while only 5 stud-
ies followed their subjects for more than 12 months (Johnston
et al., 1999; Ladwig et al., 2005; Baldwin et al., 2006; Jokinen and
Nordstrom, 2009; Baune et al., 2012). Six studies used a diagnos-
tic interview technique (Duval et al., 1996; Johnston et al., 1999;
Lanquillon et al., 2000; Arolt et al., 2003; Baldwin et al., 2006; Jang
et al., 2008) and seven studies used a depression rating scale (Kin
et al., 1997; Perez et al., 1998; Alvarez et al., 1999; Ladwig et al.,
2005; Binder et al., 2009; Baune et al., 2012; Raison et al., 2013)
while diagnostic method was not specified in one of the included
FIGURE 1 | Flow chart for the systematic review on the role of peripheral biomarkers predicting outcomes in patients with depression.
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studies (Jokinen and Nordstrom, 2009). The nature of the treat-
ment was specified in nine studies(Duval et al., 1996; Kin et al.,
1997; Perez et al., 1998; Alvarez et al., 1999; Lanquillon et al., 2000;
Arolt et al., 2003; Jang et al., 2008; Binder et al., 2009; Raison et al.,
2013); the relationship between outcome and baseline depres-
sion severity was only taken into account in 5 studies (Duval
et al., 1996; Johnston et al., 1999; Lanquillon et al., 2000; Arolt
et al., 2003; Baldwin et al., 2006). The included meta-analysis
had a variable sample size and follow-up duration depending
on the different research questions considered by the study and
the diagnostic methods used were heterogeneous including var-
ious symptoms scores and interview techniques (Ribeiro et al.,
1993).
BIOMARKERS STUDIED AND METHOD OF COLLECTION
The included studies assessed 36 different peripheral biomarkers
at baseline as a predictor of clinical outcomes. These biomark-
ers were measured in serum or plasma and could be broadly
classified as pertaining to inflammatory (n = 14), neurotrans-
mitter metabolism (n = 9), neuroendocrine (n = 8), metabolic
(n = 4), and neurotrophic (n = 1) systems. All included stud-
ies assessed statistical significance based on the criteria of having
a p-value less than 0.05. Twelve biomarkers were found to be
statistically significant in predicting outcomes (summarized in
Figure 2). Inflammatory (Lanquillon et al., 2000; Ladwig et al.,
2005; Baldwin et al., 2006; Baune et al., 2012; Raison et al., 2013)
and neuroendocrine (Ribeiro et al., 1993; Duval et al., 1996; Kin
et al., 1997; Johnston et al., 1999; Jokinen and Nordstrom, 2009)
biomarkers were each assessed in five of the included studies, fol-
lowed by neurotransmitter (Perez et al., 1998; Alvarez et al., 1999;
Johnston et al., 1999) biomarkers in three studies, neurotrophic
(Arolt et al., 2003; Jang et al., 2008) biomarker in two studies,
while metabolic (Baldwin et al., 2006) biomarkers were assessed
in only one study.
The source of peripheral biomarker measurement was plasma
in half of the included studies (n = 7) (Duval et al., 1996; Kin
et al., 1997; Perez et al., 1998; Johnston et al., 1999; Arolt et al.,
2003; Jokinen and Nordstrom, 2009; Raison et al., 2013); serum
in three studies (Ladwig et al., 2005; Jang et al., 2008; Baune
et al., 2012); whole blood (Lanquillon et al., 2000) and mixed
(both serum and plasma) (Alvarez et al., 1999) in 1 study each;
and not reported in two of the included studies (Ribeiro et al.,
1993; Baldwin et al., 2006). Four of the included studies did not
describe the procedures of measuring peripheral biomarker in
detail (Ribeiro et al., 1993; Duval et al., 1996; Baldwin et al.,
2006; Jokinen and Nordstrom, 2009). Four of the included stud-
ies describe the anticoagulant used for collecting plasma samples
with ethylenediaminetetraacetic acid (EDTA) used by two studies
(Perez et al., 1998; Raison et al., 2013); and heparin (Arolt et al.,
2003) and sodium citrate (Alvarez et al., 1999) used by one study
each.
TYPES OF CLINICAL OUTCOMES STUDIED AND STATISTICAL METHODS
The majority of included studies (n = 12) (Ribeiro et al., 1993;
Duval et al., 1996; Kin et al., 1997; Perez et al., 1998; Alvarez et al.,
1999; Johnston et al., 1999; Lanquillon et al., 2000; Arolt et al.,
2003; Baldwin et al., 2006; Jang et al., 2008; Baune et al., 2012;
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FIGURE 2 | Different outcomes in depression and their significant
predictors. This Figure describes the various mental and physical health
outcomes considered by included studies in the review, the number of
studies which examined each outcome, the peripheral biomarkers which
were found to have a statistically significant impact in predicting each
outcome and the direction of the relationship. DST, Dexamethasone
Suppression Test; CRP, C Reactive Protein; IL, Interleukin; 5HT, 5
Hydroxytryptamine; TSH, Thyroid Stimulating Hormone; ↑: higher, ↓: lower.
∗The study did not specify the source of the biomarker studied (i.e., serum or
plasma).
Raison et al., 2013) examined outcomes pertaining to mental
health or depressive symptoms, with only two studies assess-
ing physical health outcomes (Ladwig et al., 2005; Jokinen and
Nordstrom, 2009). Author defined positive treatment response to
anti-depressants with improvement in depressive symptoms [e.g.,
50% reduction in depression rating scale Hamilton Depression
Rating Scale (HDRS) from baseline] was the commonest out-
come considered by nine included studies (Ribeiro et al., 1993;
Duval et al., 1996; Kin et al., 1997; Perez et al., 1998; Alvarez
et al., 1999; Lanquillon et al., 2000; Arolt et al., 2003; Jang et al.,
2008; Raison et al., 2013). This was followed by other men-
tal health outcomes such as author defined criteria for poor
outcome of depressive symptoms (n = 3) (Ribeiro et al., 1993;
Johnston et al., 1999; Baldwin et al., 2006) for e.g., Lee andMurray
operational criteria for outcome in depression; and remission of
depression symptoms (n = 3) (Duval et al., 1996; Baune et al.,
2012; Raison et al., 2013) for e.g., HDRS <8 at follow-up. The
physical health outcomes measured were cardiovascular deaths
(n = 2) (Ladwig et al., 2005; Jokinen and Nordstrom, 2009),
myocardial infarction (n = 1) (Ladwig et al., 2005) and death
due to natural causes (n = 1) (Jokinen and Nordstrom, 2009).
The usefulness of statistical models for physical outcomes was
not compared against routinely used and evidence backed risk
scores such as the Framingham score for cardiovascular events.
Biomarkers were shown to be statistically significant in predicting
all of the six outcomes considered, including mental and physi-
cal outcomes. Figure 2 summarizes the six different mental and
physical health outcomes studied, the number of studies which
examined each outcome, the 12 peripheral biomarkers which
were noted to be statistically significant in predicting each out-
come and the direction of the relationship between the biomarker
and the outcome.
The Area Under Curve (AUC) statistic was presented only
by 1 study, with AUC statistic for Dexamethasone suppression
test (DST) reported as 0.65 for predicting increased incidence
of cardiovascular deaths only for the male subset of their sam-
ple (Jokinen and Nordstrom, 2009). DST was found to have
a significant impact in predicting three different outcomes in
Frontiers in Human Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 18 | 8
Jani et al. Peripheral biomarkers and depression assessment
two different studies; which included adverse outcomes such
as increased incidence of all-cause mortality and cardiovascular
deaths (Jokinen and Nordstrom, 2009), and favorable outcome
such as positive treatment response to anti-depressants (Kin et al.,
1997). In the included meta-analysis, DST failed to have a signif-
icant impact in predicting positive response to anti-depressants
but was significant in predicting positive response to placebo
(Ribeiro et al., 1993). Elevated levels of serum S100B was the
only biomarker which was found to have a statistically significant
role in predicting the same clinical outcome (positive treatment
response to anti-depressants) in more than one included studies
(Arolt et al., 2003; Jang et al., 2008).
PATIENT DEMOGRAPHICS AND ATTRITION RATE
Description of patient demographics, co-morbid conditions and
attrition at follow-up for included studies is provided in Table 2.
Details of the age of participants were not described by three stud-
ies (Ribeiro et al., 1993; Kin et al., 1997; Baune et al., 2012); while
information on gender distribution was missing from five studies
(Ribeiro et al., 1993; Kin et al., 1997; Arolt et al., 2003; Baldwin
et al., 2006; Baune et al., 2012). The socio-economic status of
participants was very poorly described with only two studies
(Ladwig et al., 2005; Raison et al., 2013) characterizing it and only
one study (Ladwig et al., 2005) including socio-economic sta-
tus in their statistical analysis. Patients with pre-existing chronic
disease were excluded by the majority of the included studies
(n = 8) (Duval et al., 1996; Perez et al., 1998; Johnston et al.,
1999; Lanquillon et al., 2000; Arolt et al., 2003; Ladwig et al.,
2005; Jang et al., 2008; Jokinen andNordstrom, 2009) and chronic
disease status was not considered or described by four of the
included studies (Ribeiro et al., 1993; Kin et al., 1997; Alvarez
et al., 1999; Baldwin et al., 2006). Of the two studies which
included patients with co-existing chronic disease (Baune et al.,
2012; Raison et al., 2013), only one study accounted for the num-
ber of co-morbidities in their statistical analysis (Raison et al.,
2013). The reported participant attrition rate at follow-up var-
ied from 0 to 44%; with two included studies (Ribeiro et al., 1993;
Baune et al., 2012) not specifying the details of attrition.
DISCUSSION
SUMMARY OF FINDINGS
Our review shows that blood based peripheral biomarkers were
statistically significant in predicting six different clinical out-
comes in participants with depression. Outcomes related to
both mental health (depressive symptoms) and physical health
were statistically associated with pre-treatment levels of periph-
eral biomarkers; however only two studies investigated out-
comes related to physical health. Twelve different biomarkers
related to five different biological systems (inflammatory, neu-
roendocrine, neurotransmitter metabolism, neurotrophic, and
metabolic) were found to have a potential role in predicting out-
comes of depression. Despite extensive research on the biomark-
ers of etiopathogenesis of depression, there is limited published
research exploring its translational application in clinical practice.
Furthermore, the research is of generally limited quality and lacks
clinical utility.
The included studies have several methodological problems.
The study sample size was small and follow-up duration was short
in the majority of included studies. The majority of included
studies used questionnaire scores using symptom count for diag-
nosing depression at baseline, while the gold standard interview
technique for depression diagnosis was used only by a minority.
Baseline severity of depressive symptoms assessed using symp-
tom count is associated with higher rate of relapse in patients
with depression (Ishak et al., 2013) but accounting for the base-
line severity of depressive symptoms was only undertaken by a
minority of studies. There is a strong evidence base suggesting
that depression is two to three time more prevalent in patients
with co-existing chronic disease as compared to the general pop-
ulation (Egede, 2007; Moussavi et al., 2007; Mitchell et al., 2013)
but the effect of co-morbidity on clinical outcomes was examined
by only two studies.
Importantly, the clinical implications of the observed statisti-
cal relationships in the included studies were not well explained.
The c-statistic or area under receiver operating characteristic
(ROC) curve (Cook, 2007), which is regarded as one of the stan-
dard methods for evaluating clinical discriminating power of a
statistical model, was reported by only one study. The useful-
ness of statistical models for physical outcomes in the included
study was not compared against robustly validated and routinely
used risk scores such as the Framingham score for cardiovascular
events (D’Agostino et al., 2008). Finally, some of the biomarkers
included in this review are complicated tomeasure and likely to be
expensive. The source and method of measurement for biomark-
ers in the included studies were heterogeneous and this may have
an influence on assay levels of the biomarkers measured (Tort
et al., 2003; Wong et al., 2008; Yu et al., 2011). The cost impli-
cations of doing these tests were not considered in detail in the
included studies and this is likely to be a relevant factor when
considering their potential use in routine clinical practice. There
is some evidence that peripheral biomarkers may have a role
in stratifying depression severity by means of predicting various
physical and mental health outcomes in depression but further
more robust research needs to be done in this area to address the
shortcomings of the available evidence.
OUTCOMES BASED APPROACH IN DEPRESSION SEVERITY
STRATIFICATION
The use of prediction rules and biomarkers to inform clinical
decision making is not a novel concept. It has been used in mak-
ing management decisions in a wide variety of clinical scenarios
such as patients presenting with high cholesterol, atrial fibril-
lation, chest pain, ankle injury, and intensive care (Reilly and
Evans, 2006). In psychiatry, it has been proposed to use this
principle for predicting inpatient violence (Abderhalden et al.,
2006). Depression contributes to disease burden not only owing
to reduction in quality of life and functional productivity, but
also due to the increased risk of adverse physical outcomes such
as hospitalization and mortality (Ferrari et al., 2013). There is
strong evidence showing an association of depression (MDD and
mild depression) with increased risk of adverse physical out-
comes such as all-cause mortality, cardiovascular disease, hyper-
tension, stroke, diabetes, alzeimer’s disease, obesity, and cancer
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Table 2 | Patient population and attrition rates in included studies.
Study Mean Age in years (Standard
Deviation, if available) and Sex
F, Females; M, Males
Socio-economic status Co-morbid medical conditions Participant numbers
Number of participants
at baseline (B) and
follow-up(FU); attrition
in percentage
Alvarez et al., 1999 45 (13.8)
6F, 2M
Not described Not described 10 B
8 FU 20% attrition
Arolt et al., 2003 46.4 (9.8)
Not described
Not described Patients with co-morbid
conditions excluded from study
25 B
25 FU No attrition
Baldwin et al., 2006 73.9
Not described
Not described Not described 50 B
28 FU 44% attrition
Baune et al., 2012 Not described Not described Presence/absence of a list of
medical conditions noted and
entered into statistical analysis
73 B
Sample size at follow-up
not specified
Duval et al., 1996 39.8 (12.9);
19M, 11F
Not described Patients with co-morbid
conditions excluded from study
30 B
30 FU No attrition
Jang et al., 2008 60.3;
43F, 16M
Not described Patients with co-morbid
conditions excluded from study
59 B
59 FU No attrition
Johnston et al., 1999 47;
24F, 10M
Not described Patients with co-morbid
conditions excluded from study
47 B
34 FU 27.6% attrition
Jokinen and
Nordstrom, 2009
52 (16.4);
256F, 126M
Not described Patients with co-morbid
conditions excluded from study
382 B
346 FU 9.4% attrition
Kin et al., 1997 Not described Not described Not described 95 B
70 FU 26.3% attrition
Ladwig et al., 2005 57.75 (7.8);
975M
Education status
described and entered
into statistical analysis
Patients with co-morbid
conditions excluded from study
986 B
975 FU 1.1% attrition
Lanquillon et al.,
2000
53.5;
15F, 9M
Not described Patients with co-morbid
conditions excluded from study
35 B
24 FU 30.5% attrition
Perez et al., 1998 M 45 (2.9), F 44.9 (2.0);
59F, 24M
Not described Patients with co-morbid
conditions excluded from study
89 B
83 FU 6.7% attrition
Raison et al., 2013 42.5(8.2) placebo group, 44.3
(9.4) intervention group;
40F, 20M
Education and
employment status
described but not
entered into statistical
analysis
Notable exclusions- previous
history of cancer, history of
unstable cardiovascular,
endocrinologic, hematologic,
hepatic, renal, or neurologic
disease (determined by
Physical examination and
laboratory testing).
Number of co-morbid medical
conditions noted and entered into
statistical analysis
60 B
60 FU No attrition
Ribeiro et al., 1993 Not described Not described Not described Not described
(Penninx et al., 2013). Physical adverse outcomes associated with
depression attribute to a significant amount of morbidity and
mortality (Ferrari et al., 2013; Penninx et al., 2013). Consequently,
it is imperative that the risk of adverse physical outcomes
associated with depression should be considered while taking
decisions regarding depression severity stratification and subse-
quent management. Crucially, the clinical utility of biomarkers
in predicting physical outcomes in depression, if any, should be
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compared and validated against some of the established and avail-
able risk scoring systems (e.g., Framingham, D’Agostino et al.,
2008) for physical outcomes.
ROLE OF PERIPHERAL BIOMARKERS IN IDENTIFYING DEPRESSION
SUBTYPES
The use of peripheral biomarkers in identifying different subtypes
of depression has been explored by other studies in the litera-
ture. A meta-analysis reviewing the association between HPA axis
hyperactivity (Dexamethasone non-suppression) and depression
suggested a dose-response relationship, with patients with mild
depression showing higher HPA hyperactivity compared to con-
trols but lower than that of patients with MDD (Stetler and
Miller, 2011). Peripheral inflammatory markers such as Tumor
necrotic factor (TNF)-α and IL (Interleukin)-6, serum neopterin
have been shown to have association with melancholic subtypes
of MDD (Maes et al., 2012; Dunjic-Kostic et al., 2013). A review
of metabolic and neuroendocrine biomarkers (Body mass index
BMI, waist-hip ratio, fasting glucose, serum adrenocorticotropic
hormone ACTH) in pre-menopausal women with MDD sup-
ported their role in identifying three different subtypes of MDD-
melancholic, atypical and undifferentiated (Cizza et al., 2012).
This suggests that peripheral biomarkers may have a useful role
in addressing some of the challenges posed by heterogeneity of
depression, with a particular biomarker likely to have a more use-
ful role in a specific subtype of depression. However, before any
decisions are made, much better high quality research is needed.
NOVEL BIOMARKERS IN DEPRESSION
In recent years, novel techniques in proteomics, metabolomics,
genetics, and epigenetics have led to several new biomarkers
being proposed in depression. Proteomic techniques have been
used to identify nine differentiating proteins belonging to lipid
metabolism and immune system from treatment naïve patients
with depression, when compared against healthy controls (Xu
et al., 2012). Similarly, metabolomic techniques such as nuclear
magnetic response (NMR) based analysis of both urine and
plasma have been utilized to identify differentiating proteins
related to lipid metabolism and neurotransmitter system with
good accuracy in treatment naïve patients with depression, when
compared to healthy controls (Zheng et al., 2012a,b). The role
of brain-derived neurotrophic gene polymorphisms, glucocorti-
coid receptor polymorphism and serotonin gene receptor have
been studied in diagnosis and prognostification of depression
with some encouraging results (Chi et al., 2010; Szczepankiewicz
et al., 2011; Uher et al., 2011). Although the findings from genome
wide association studies (GWAS) till date in depression have failed
to make a major breakthrough, they may have a potential role
in stratification of depression and further research is ongoing
(Wray et al., 2012; Flint and Kendler, 2014). Thus, these emerging
techniques and biomarkers may have a role in diagnosis, iden-
tifying specific subtypes of depression and prognostification in
depression (Schneider and Prvulovic, 2013).
MULTIPLE BIOMARKERS, ALLOSTATIC LOAD, AND DEPRESSION
The term allostasis refers to the adaptive physiological responses
organisms activate when homeostasis is disrupted during acute
stress, real or interpreted threats (McEwen and Stellar, 1993).
When chronically activated, allostatic mechanisms become phys-
iologically taxing—or an allostatic load (AL)—that consequently
increase one’s susceptibility to disease (McEwen, 1998). There is
some early evidence to suggest that an index comprising multiple
biomarkers or AI may exhibit a stronger relationship with depres-
sive symptoms, especially in elderly populations, when compared
with examination of individual biomarkers in isolation (Juster
et al., 2011). The role of multiple biomarkers in risk assessment
and predicting outcomes in patients with depression needs to be
explored and compared against the role of individual biomarkers.
LIMITATIONS
Our search strategy was limited to studies published in English
language. A variety of other biomarkers such as genetic, imaging
and CSF biomarkers may have a role in depression stratifica-
tion by predicting clinical outcomes (Schneider and Prvulovic,
2013). However, this review considered only peripheral or blood-
based biomarkers used in current clinical practice due to their
comparative non-invasive nature and ease of measurement. The
uncertainty surrounding management decisions in patients with
depression in current practice is a particular issue at the time
of initial presentation (Davidson, 2010). Hence, this review was
focussed on addressing the issue of the use of peripheral biomark-
ers at baseline or pre-treatment as a predictive tool of clinical out-
come (both mental and physical) and not on assessing changes in
a peripheral biomarker level following treatment for depression.
FUTURE RESEARCH
There is a need for further research in this area, involving large
scale studies with longer duration of follow-up, better charac-
terization of patient populations and inclusion of patients with
chronic diseases. An “ideal” scientific process for a biomarker
evaluation in clinical risk discrimination has been highlighted
in other fields such as cardiovascular disease, a similar approach
can be adopted for biomarkers of depression (Welsh et al., 2008).
Further epidemiological studies of greater quality which min-
imize potential bias and evaluate clinical utility are urgently
needed. Future studies also need to incorporate other physical
health outcomes such as rate of cardiovascular events, incidence
of cancer and all-cause mortality associated with depression and
compare validity against established benchmarks, along with
mental health outcomes related to depression symptoms.
CONCLUSION
Pre-treatment levels of 12 different blood based peripheral
biomarkers related to five different biological pathways were
found to have a statistically significant relationship with outcomes
in patients with depression. Six different outcomes in depres-
sion were predicted using these biomarkers, pertaining to both
physical and mental health, but the clinical implications remain
unclear. It appears likely that peripheral biomarkers may have an
important role in helping clinicians to stratify depression severity
and to predict clinical outcomes. However, the available evidence
has multiple methodological limitations which must be over-
come to make any real clinical headway; in particular, interaction
between these biomarkers, depressive symptoms and co-morbid
physical conditions needs to be explored further.
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